Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Details

Serval ID
serval:BIB_7EBF877C0A3C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Journal
American Journal of Tropical Medicine and Hygiene
Author(s)
Herrera S., Fernández O.L., Vera O., Cárdenas W., Ramírez O., Palacios R., Chen-Mok M., Corradin G., Arévalo-Herrera M.
ISSN
1476-1645 (Electronic)
ISSN-L
0002-9637
Publication state
Published
Issued date
2011
Volume
84
Number
2 Suppl
Pages
12-20
Language
english
Abstract
We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 μg/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in > 90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.
Keywords
Adjuvants, Immunologic/administration & dosage, Adolescent, Adult, Animals, Antibodies, Protozoan/blood, Dose-Response Relationship, Immunologic, Drug Toxicity, Female, Humans, Immunoglobulin G/blood, Injections, Intramuscular, Interferon-gamma/metabolism, Leukocytes, Mononuclear/metabolism, Malaria Vaccines/adverse effects, Malaria Vaccines/immunology, Malaria, Vivax/prevention & control, Male, Mannitol/administration & dosage, Mannitol/analogs & derivatives, Oleic Acids/administration & dosage, Plasmodium vivax/immunology, Protozoan Proteins/immunology, Time Factors
Pubmed
Web of science
Open Access
Yes
Create date
27/10/2011 13:47
Last modification date
20/08/2019 14:39
Usage data